Abstract:Inflammatory bowel disease (IBD) is a chronic and recurrent condition affecting the gastrointestinal tract. Disturbed gut microbiota and abnormal bile acid (BA) metabolism are notable in IBD, suggesting a bidirectional relationship. Specifically, the diversity of the gut microbiota influences BA composition, whereas altered BA profiles can disrupt the microbiota. IBD patients often exhibit increased primary bile acid and reduced secondary bile acid concentrations due to a diminished bacteria population essential for BA metabolism. This imbalance activates BA receptors, undermining intestinal integrity and immune function. Consequently, targeting the microbiota-BA axis may rectify these disturbances, offering symptomatic relief in IBD. Here, the interplay between gut microbiota and bile acids (BAs) is reviewed, with a particular focus on the role of gut microbiota in mediating bile acid biotransformation, and contributions of the gut microbiota-BA axis to IBD pathology to unveil potential novel therapeutic avenues for IBD.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is in the treatment of inflammatory bowel disease (IBD), by targeting the gut microbiota - bile acid axis to correct the imbalance of gut microbiota and bile acid metabolism, thereby providing new treatment methods for IBD patients. Specifically, the paper explores the interaction between gut microbiota and bile acids and their roles in IBD pathology, aiming to reveal potential new treatment pathways. ### Background of the paper - **Overview of IBD**: IBD is a chronic relapsing disease that affects the gastrointestinal tract, including Crohn's disease (CD) and ulcerative colitis (UC). - **Relationship between gut microbiota and bile acids**: The gut microbiota diversity in IBD patients is decreased, and bile acid metabolism is abnormal, manifested as an increase in primary bile acids and a decrease in secondary bile acids. This imbalance activates bile acid receptors and impairs intestinal barrier function and immune function. - **Current treatment situation**: Current microbial therapies such as fecal microbiota transplantation (FMT), probiotics, and engineered bacteria have been clinically applied, but their mechanisms of action are not fully understood. ### Objectives of the paper - **Clarify the mechanism**: Describe in detail how the gut microbiota mediates the biotransformation of bile acids and how these changes are manifested in IBD patients. - **Explore new therapies**: Based on the gut microbiota - bile acid axis, propose new IBD treatment methods and provide new insights for clinical prevention, treatment, and diagnosis. ### Main content 1. **Gut microbiota - bile acid axis**: - **Gut microbiota mediates bile acid metabolism**: Through processes such as deconjugation, 7α/7β - dehydroxylation, oxidation/epimerization, etc., change the composition of the bile acid pool. - **Bile acids reshape the gut microbiota**: Bile acids, as potent antibacterial agents, kill bacteria by disrupting cell membranes and indirectly regulate the composition of the gut microbiota through receptors such as FXR and TGR5. 2. **Bile acid biotransformation mechanism**: - **Deconjugation reaction**: Catalyzed by bile salt hydrolase (BSH), releasing free bile acids. - **7α/7β - dehydroxylation**: Catalyzed by enzymes encoded by the bai gene, converting primary bile acids into secondary bile acids. - **Oxidation and epimerization**: Catalyzed by 3α -, 3β -, 12α - hydroxysteroid dehydrogenase (HSDH), changing the hydroxyl position and properties of bile acids. ### Conclusion Through in - depth research on the interaction of the gut microbiota - bile acid axis and its role in IBD pathology, it can provide theoretical and experimental bases for the development of new IBD treatment methods. This not only helps to improve the symptoms of IBD patients but may also provide new ideas for the treatment of other related diseases.

Novel approaches in IBD therapy: targeting the gut microbiota-bile acid axis

Bile Acid–Gut Microbiota Axis in Inflammatory Bowel Disease: From Bench to Bedside

The influence of bile acid, microbiota and their interaction on inflammatory bowel disease and the related progress in clinical application

Anti-cytokine Therapy and Small Molecule Agents for the Treatment of Inflammatory Bowel Disease

Bile acids as signaling molecules in inflammatory bowel disease: Implications for treatment strategies

Regulation of gut microbiota-bile acids axis by probiotics in inflammatory bowel disease

The gut microbes in inflammatory bowel disease: Future novel target option for pharmacotherapy

Targeting the Intestinal Microbiota: A Novel Direction in the Treatment of Inflammatory Bowel Disease

Gut microbial metabolome in inflammatory bowel disease: From association to therapeutic perspectives

Intestinal Crosstalk between Bile Acids and Microbiota in irritable bowel syndrome

Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome

An (Anti)-Inflammatory Microbiota: Defining the Role in Inflammatory Bowel Disease?

Recent progress on engineered micro/nanomaterials mediated modulation of gut microbiota for treating inflammatory bowel disease

The interaction of bile acids and gut inflammation influences the pathogenesis of inflammatory bowel disease

The microbiome in inflammatory bowel diseases: from pathogenesis to therapy

Lactic Acid Bacteria-Gut-Microbiota-Mediated Intervention towards Inflammatory Bowel Disease

The emerging role of the gut microbiota and its application in inflammatory bowel disease

Gut microbiota and inflammatory bowel disease: The current status and perspectives

Bile Acid-Related Regulation of Mucosal Inflammation and Intestinal Motility: From Pathogenesis to Therapeutic Application in IBD and Microscopic Colitis

Postbiotics in inflammatory bowel disease: efficacy, mechanism, and therapeutic implications